Document is current
Any future updates will be listed below
-
Authors
Husvogt, Lennart
Yaghy, Antonio
Camacho, Alex
Lam, Kenneth
Schottenhamml, Julia
Ploner, Stefan B.
Fujimoto, James G.
Waheed, Nadia K.
Maier, Andreas
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (508075009)
Friedrich-Alexander-Universität Erlangen-Nürnberg
- License Information
-
More Information
Article History
Received: 16 June 2023
Accepted: 6 September 2024
First Online: 14 September 2024
Competing interests
: Stefan Ploner and Dr Fujimoto hold a patent related to VISTA-OCTA. Dr Fujimoto holds stock in Optovue and has received funding from Topcon. Dr Waheed is employed by Applied Genetic Technologies Corporation, has consulted for Complement Therapeutics Ltd, Iolyx Pharmaceuticals, Hubble, Olix Pharma, Saliogen, Syncona, and Topcon, has received funding from Topcon, Nidek, and Zeiss, and has personal financial interests in Gyroscope Therapeutics Ltd and Ocudyne. All other authors declare no competing interest.
